EMA’s human medicine committee recommends marketing approval for acoramidis for treatment of transthyretin amyloid cardiomyopathy: Berlin Monday, December 16, 2024, 13:00 Hrs [I ...

The findings could potentially enable patients to be identified and treated before symptoms of ATTR-CM emerge.

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on ...

Pfizer has awarded $80,000 to Rutgers Robert Wood Johnson Medical School (RWJMS) to fund an Amyloidosis Fellowship at Robert ...

for acoramidis for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered ...

Piper Sandler analyst Biren Amin maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today and set a price target of $46.00.